caa a22 4500 44533469X CHVBK 20180317142750.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1245/s10434-011-1988-5 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1988-5 Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma [Elektronische Daten] [Nick Verwer, Richard Scolyer, Roger Uren, Julie Winstanley, Philip Brown, Johannes de Wilt, John Thompson] Background: Interval sentinel nodes (SNs) are lymph nodes receiving direct lymphatic drainage from a primary site and lying between the tumor and a recognized node field. It is not clear what further nodal surgery should be performed when interval nodes are found to contain micrometastatic disease. In this study, the incidence, location, and treatment of interval SNs in melanoma patients were analyzed to develop recommendations regarding the treatment of patients with interval SNs. Methods: A retrospective review was undertaken of all patients with primary cutaneous melanoma who underwent lymphoscintigraphy at a single institution between 1992 and 2007. Data concerning the primary melanoma, location of SNs, treatment and survival were analyzed. Results: Of 4895 patients who had a lymphoscintigram during the study period, 442 (9.0%) had an interval SN identified on lymphoscintigraphy. Interval SNs occurred significantly more often in patients with melanomas on the posterior trunk than in those with melanomas at other sites (P<0.001). A total of 197 patients (44.6%) with an identified interval SN underwent excision biopsy of the node. Of the 16 patients found to have metastatic melanoma in their interval SN, four also had negative SNs in a recognized lymph node field, and no other positive nodes were found on completion lymphadenectomy. Conclusions: Interval SNs are present in approximately 1 in 10 melanoma patients but are about half as likely to contain metastases as SNs in recognized node fields. If a positive interval SN is found, completion lymphadenectomy of the recognized lymph node field is only recommended if a SN in this field is also positive. Society of Surgical Oncology, 2011 Verwer Nick Melanoma Institute Australia, Sydney, Australia aut Scolyer Richard Melanoma Institute Australia, Sydney, Australia aut Uren Roger Melanoma Institute Australia, Sydney, Australia aut Winstanley Julie Melanoma Institute Australia, Sydney, Australia aut Brown Philip Melanoma Institute Australia, Sydney, Australia aut de Wilt Johannes Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands aut Thompson John Melanoma Institute Australia, Sydney, Australia aut Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3292-3299 1068-9265 18:12<3292 2011 18 10434 https://doi.org/10.1245/s10434-011-1988-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1988-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Verwer Nick Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 700 1- Scolyer Richard Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 700 1- Uren Roger Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 700 1- Winstanley Julie Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 700 1- Brown Philip Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 700 1- de Wilt Johannes Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands aut NATIONALLICENCE 700 1- Thompson John Melanoma Institute Australia, Sydney, Australia aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3292-3299 1068-9265 18:12<3292 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer